46 research outputs found
Pentoxifylline Prevents Autoimmune Mediated Inflammation in Low Dose Streptozotocin Induced Diabetes
Xanthine derivative, pentoxifylline (PTX), has been recently shown to exert a protective effects
in certain animal models of autoimmunity, including diabetes in NOD mice. In the present
study, the immunomodulatory potential of PTX was investigated in autoimmune diabetes
induced by multiple low doses of streptozotocin (MLD-SZ) in genetically susceptible CBA/H
mice (tested with 40 mg SZ/kg b.w. for 5 days) and DA rats (tested with 20 mg/kg b.w. for 5
days). In both species, 2 ā 3 weeks following the MLD-SZ treatment, sustained hyperglycemia
developed, as an outcome of inflammatory reaction with endothelial cell activation and accumulation
of mononuclear cells. Although there was no evidence of typical insulitis in early disease
development (day 10), in both rats and mice, macrophages, CD4+ and CD8+ cells were present in the islets of Langerhans as diffuse mononuclear infiltrates with the expression of
IFN-Ī³ and inducible NO synthase (iNOS). Administration of PTX (200 mg/kg/day for 10 days)
in combination with MLD-SZ reduced insulitis and the production of mediators tested, and prevented
the development of hyperglycemia. These results suggest that beneficial effects of PTX
involve down-regulation of local proinflammatory cytokine-mediated NO synthase pathway.
They also demonstrate that in addition to ameliorating spontaneous autoimmunity in NOD
mice, PTX may be effective in downregulating an inflammatory autoimmune process triggered
in susceptible host by an external agents, such as streptozotocin
Neutralization of macrophage migration inhibitory factor - novel approach for the treatment of immunoinflammatory disorders
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that plays an important role in the pathogenesis of numerous inflammatory and autoimmune disorders. As such, it is an attractive therapeutic target for the treatment of these disorders. Several groups of possible MIF inhibitors have so far been identified, including anti-MIF antibodies, small chemical compounds and plant-derived inhibitors. This review presents current understanding of the effects of MIF neutralization in a number of experimental animal models of inflammatory and autoimmune diseases and discusses the potential problems in translating this kind of therapy into human subjects. (c) 2006 Elsevier B.V. All rights reserved.nul
MIF and insulin: Lifetime companions from common genesis to common pathogenesis
Pro-inflammatory nature of macrophage migration inhibitory factor (MIF) has been generally related to the
propagation of inflammatory and autoimmune diseases. But this molecule possesses many other peculiar
functions, unrelated to the immune system, among which is its supportive role in the post-translational modifications of insulin. In this way MIF enables proper insulin conformation within the pancreatic beta cell and its full activity. The inherent or acquired changes in MIF expression might therefore lead to different insulin processing and initiation of autoimmunity. The relation between MIF and insulin does not stop at this point; these two molecules continue to interact during pathological states characterized by inflammation and insulin resistance. In this context, MIF indirectly and negatively influences insulin action by boosting inflammatory environment and disabling target cells to respond to insulin. On the other side, insulin might interfere with MIF action as well, acting as an anti-inflammatory mediator. Therefore, the proper interaction between MIF and insulin is crucial for maintaining homeostasis, while anti-inflammatory therapies based on the systemic MIF blockage may disturb this balance. This review covers MIF-insulin relationship in the physiological and pathological conditions and discusses the approaches for MIF inhibition and their net effect specifically considering possible impact on insulin misfolding and the possible misinterpretation of previous results due to the discovery of MIF functional homolog D-dopachrome tautomerase
Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms
Mycophenolic acid (MPA) and A77 1726, the active components of the immunosuppressants mycophenolate mophetil and leflunomide, respectively, in a dose-dependent manner inhibited interferon (IFN)-gamma/LPS-induced interleukin (IL)-6 release in confluent cultures of mouse L929 fibrosarcoma cells. In addition, both drugs markedly reduced the production of the free radical gas nitric oxide (NO), without affecting the viability of L929 cells. The inhibitors of NO synthase, aminoguanidine and L-NMMA, but not L-NMMA inactive counterpart D-NMMA, mimicked the effects of A77 1726 and MPA on IL-6 generation in L929 fibroblasts. Furthermore, NO-releasing substance SNP completely reverted IL-6 accumulation in L929 cultures treated with A77 1726, while only partial recovery of IL-6 production was observed in the presence of MPA. MPA, but not A77 1726, significantly suppressed NO-independent IL-6 release triggered by cAMP-elevating agent rolipram. Thus, while A77 1726 effect on IL-6 production was mediated through concomitant reduction of NO synthesis, MPA action was mainly independent of the interference with NO generation. Finally, both agents inhibited IFN-gamma/LPS-triggered IL-6 production in mouse primary fibroblasts, but not in mouse peritoneal macrophages, indicating cell-specificity of this novel anti-inflammatory action of A77 1726 and MPA
Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts
Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts as a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH). MMF has recently been shown to inhibit the enzymatic activity of inducible NO synthase (iNOS) and subsequent production of the cytotoxic free radical nitric oxide (NO) in endothelial cells. We here investigated the effect of bioactive MMF compound mycophenolic acid (MPA) on iNOS-mediated NO synthesis in fibroblasts, which are important source of NO in rheumatoid arthritis and during rejection of solid organ transplants. MPA exerted dose-dependent inhibition of NO synthesis, measured as nitrite accumulation, in IFN-gamma + LPS-stimulated L929 mouse fibroblast cell line and rat primary fibroblasts. The effect of MPA was not mediated through interference with IMPDH-dependent synthesis of iNOS co-factor BH4 and subsequent suppression of iNOS enzymatic activity, as direct BH4 precursor sepiapterin failed to block the action of the drug. MPA suppressed the IFN-gamma + LPS-induced expression of fibroblast iNOS protein, as well as mRNA for iNOS and its transcription factor IRF-1, as assessed by cell-based ELISA and semiquantitative RT-PCR, respectively. MPA suppression of fibroblast NO release, iNOS, and IRF-1 activation, was efficiently prevented by exogenous guanosine, indicating that the drug acted through reduction of IMPDH-dependent synthesis of guanosine nucleotides. These results suggest that MPA inhibits NO production in fibroblasts by blocking guanosine nucleotide-dependent expression of iNOS gene, through mechanisms that might involve the interference with the induction of iNOS transcription factor IRF-1.nul
Dry olive leaf extract (DOLE) down-regulates the progression of experimental immune-mediated diabetes by modulation of cytokine profile in the draining lymph nodes
We have recently demonstrated the beneficial effects of dry olive leaf extract (DOLE) in two preclinical models of type 1 diabetes. Here we analyze the potential mechanisms underlying diabetes amelioration at the level of lymph node drainage. Treatment of C57BL/6 mice with DOLE during induction of diabetes with multiple low doses of streptozotocin (MLD-SZ) modulated cytokine expression and production in pancreatic lymph node cells, thereby changing the balance between potentially pathogenic and down-regulating cytokines. These results support the immunoregulatory potential of DOLE which takes place at the level of lymph node drainage and preserves the target tissue from autoimmune attack
Carbon Monoxide-Releasing Molecule-A1 Inhibits Th1/Th17 and Stimulates Th2 Differentiation In vitro
Carbon monoxide (CO) is endogenously produced by haeme oxygenase-1 and
has profound effects on intracellular signalling processes, generating
anti-inflammatory, antiproliferative and antiapoptotic effects. A
boron-containing compound CORM-A1 is capable of releasing CO in such a
way to mimic physiological functions of haeme oxygenase-1. Considering
the importance of Th1/Th17 versus Th2 balance in the final outcome of
immune and inflammatory responses in this study we focused on
immune-modulatory effects of CORM-A1 on murine lymph node-derived T
cells in vitro and its influence on T-cell proliferation, activation and
differentiation. Anti-CD3/CD28 antibody-triggered lymph node cells
proliferation remained unaffected after 24-hour CORM-A1 treatment, as
well as the expression of the early activation marker CD25. However,
CORM-A1 successfully reduced the secretion of the two representative
pro-inflammatory cytokines, IFN-gamma and IL-17, while the secretion of
anti-inflammatory cytokine IL-4 remained unchanged. Furthermore, CORM-A1
efficiently reduced the percentage of CD4(+)IFN-gamma(+) and
CD4(+)IL-17(+) cells, whereas CD4(+)IL-4(+) cell population increased
after treatment. Also, CORM-A1 significantly reduced expression of
transcription factor ROR gamma T, necessary for Th17 development, but
the expression of Th1-related and Th2-related transcription factors
(T-bet and GATA-3, respectively) remained unchanged. In conclusion, our
findings indicate that CO has anti-inflammatory role through the
regulation of balance between pro-inflammatory Th1/Th17 and
anti-inflammatory Th2 cells. Observed immunomodulatory effects of
CORM-A1 could be useful for developing novel therapeutic approaches in
managing Th1/Th17-mediated immune disorders.EFSD New Horizons Collaborative Research Initiative; Ministry of
Education, Science and Technological Development, Republic of Serbia
{[}173013
The inhibitory effect of human macrophage inflammatory protein-1 alpha (LD78) on acute myeloid leukemia cells in vitro
Macrophage inflammatory protein-la (MIP-1a) has recently been shown to inhibit proliferation of immature hemopoietic progenitors. In addition, significant inhibition of early and mature leukemic progenitors in acute myeloid leukemia (AML) has been obtained with MIP-1 alpha. We performed a study of 25 AML patients at diagnosis to evaluate the effect of a human homolog of MIP-1 alpha (LD78) on bone marrow (BM) and peripheral blood (PB) leukemic progenitors (colony-forming unit-AML [CFU-AML]) and AML cell proliferation. A methylcellulose culture system was used for CFU-AML and incorporation of H-3-TdR for AML cell proliferation, We found that LD78 inhibits CFU-AML colony formation up to 100% for the BM in 14/16 samples studied with the average maximal inhibition of 62.7 +/- 9.1% and up to 100% for the PB in 12/13 samples studied with the average maximal inhibition of 71.4 +/- 9.9%. In addition to this, LD78 inhibited AML cell proliferation up to 60% for the BM in 10/18 samples studied with the average maximal inhibition of 17.8 +/- 3.5%, and up to 87.1% for the PB cell proliferation in 10/16 samples studied with the average maximal inhibition of 27.5 +/- 6.8%, Our results have shown that LD78 is more active on AML progenitors than on AML cell proliferation, Inhibition of the AML cells, although less than that of the progenitors, indicates that more limited activity of LD78 on more mature leukemic cells is present in AML.nul
Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes
Oxidative stress makes an important contribution to the development of autoimmune diabetes. We therefore tested the possible therapeutic value of two anti-oxidants, butylated hydroxyanisole (BHA) and pyrrolidine dithiocarbarnate (PDTC), in the animal model of diabetes induced in susceptible DA rats by multiple low doses of streptozotocin (MLD-SZ, 20 mg/kg/day for 5 days). Administration of either BHA, or PDTC (50 mg/kg/day for 7 days), after finishing MLD-SZ injections, attenuated both the development of hyperglycemia and insulitis. Ex vivo analysis revealed that BHA treatment reduced the proliferation of autoreactive lymphocytes and down-regulated their adhesion to endothelium. In addition, BHA markedly attenuated the production of proinflammatory cytokines 1L-1beta and TNF-alpha by both islets of pancreas and peritoneal macrophages. In parallel, macrophage release of cytotoxic oxygen and nitrogen intermediates superoxide anion (O-2.(-)) and nitric oxide (NO.), respectively, was significantly inhibited. Finally, BHA treatment reduced intrapancreatic expression of inducible NO synthase (iNOS) and consequent production of NO. by pancreatic islets. Together, these data indicate that antioxidant agents might be a feasible therapeutic tools to interfere with development of autoimmune diabetes at multiple levels, including lymphocyte proliferation and adhesion, as well as the production of proinflammatory and cytotoxic mediators. (C) 2004 Elsevier Ltd. All rights reserved.nul